Palatin Technologies, Inc. lead product candidate, Rekynda
09-Jan-17
$465 million

Target:
Palatin Technologies, Inc. lead product candidate, Rekynda

Acquiror:
AMAG Pharmaceuticals, Inc.
Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.